(Total Views: 293)
Posted On: 05/04/2018 5:00:16 PM
Post# of 72440
We are going to soon get 1 hell of a deal from BP for B-OM.
A recent online article published by Baystreet.ca, in follow-up to an earlier one, similarly places Brilacidin-OM in a leading competitive position as multiple pharmaceutical companies look to obtain the first-ever marketing approval for a drug to treat Severe Oral Mucositis (SOM) in Head and Neck Cancer (HNC) patients receiving chemoradiation.
The article characterizes Brilacidin-OM as a potential “category creator” in the OM space -- estimated to be approximately a $1 billion annual market opportunity
A recent online article published by Baystreet.ca, in follow-up to an earlier one, similarly places Brilacidin-OM in a leading competitive position as multiple pharmaceutical companies look to obtain the first-ever marketing approval for a drug to treat Severe Oral Mucositis (SOM) in Head and Neck Cancer (HNC) patients receiving chemoradiation.
The article characterizes Brilacidin-OM as a potential “category creator” in the OM space -- estimated to be approximately a $1 billion annual market opportunity
(0)
(0)Scroll down for more posts ▼
